Albireo to Report Q3 2022 Financial Results on November 8, 2022
October 31 2022 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced that
management will host a conference call and live audio webcast
at 4:30 p.m. ET on November 8, 2022, to provide a
business update and review the company’s financial results for the
quarter ended September 30, 2022.
To access the live conference call by phone, dial
1-855-327-6837 (domestic) or 1-631-891-4304 (international),
and provide the access code 10020423. A live audio webcast will be
accessible from the Investors page at ir.albireopharma.com/.
To ensure a timely connection to the webcast, it is recommended
that participants register at least 15 minutes prior to the
scheduled start time. An archived version of the webcast will be
available for replay on the Events & Presentations section of
the Investors page of Albireo’s website for 3 months following the
event.
About Albireo
Albireo Pharma is a rare disease company focused on
the development of novel bile acid modulators to treat pediatric
and adult liver diseases. Albireo’s lead product, Bylvay, was
approved by the U.S. FDA as the first drug for the treatment of
pruritus in all types of progressive familial intrahepatic
cholestasis (PFIC), and it is also being developed to treat other
rare pediatric cholestatic liver diseases with a completed Phase 3
trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in
biliary atresia, as well as Open-label Extension (OLE) studies for
PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of
PFIC in Germany, England, Wales & Northern Ireland, Scotland,
Italy, and Belgium. The Company has also completed a Phase 1
clinical trial for A3907 to advance development in adult
cholestatic liver disease, with IND-enabling studies progressing
with A2342 for viral and cholestatic liver disease. Albireo was
spun out from AstraZeneca in 2008 and is headquartered in Boston,
Massachusetts, with its key operating subsidiary in Gothenburg,
Sweden. For more information on Albireo, please visit
www.albireopharma.com.
Media Contacts:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans
Vitzthum, LifeSci Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024